戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ociated with suboptimal ART adherence and/or drug absorption.
2 sed and prolonged ocular surface contact and drug absorption.
3 ciated with sub-optimal ART adherence and/or drug absorption.
4 tine are crucial tools for the prediction of drug absorption.
5 optimizing ASD formulations to maximize oral drug absorption.
6 e of IUDs, have extremely low or no systemic drug absorption.
7  formulation in vivo and consequently affect drug absorption.
8 valuate their potential impact on intestinal drug absorption.
9 ASBT) may serve as a prodrug target for oral drug absorption.
10 e of 100 to 1,600 mg/d, suggesting saturable drug absorption.
11 hich simultaneously improve both potency and drug absorption.
12 n of drug permeation and in vivo fraction of drug absorption.
13 h high-grade SAH exhibited severely impaired drug absorption.
14 it vessels significantly affects macroscopic drug absorption.
15 the impact of fish life stage and species on drug absorption (A) via multiple routes; the potential i
16                 Given its role in intestinal drug absorption, a detailed analysis of the mechanisms t
17 ell model has been widely employed to assess drug absorption across the intestine.
18                      Amino acid (and related drug) absorption across the human small intestinal wall
19 lidation and determining the role of P-gp in drug absorption and disposition.
20  shown to play an important role in limiting drug absorption and distribution and in enhancing drug c
21 ycoprotein may play an important role in net drug absorption and drug/drug interactions of shared CYP
22 and drugs to predict the impact of lipids on drug absorption and enable rational design of lipid-base
23 of these agents may be to enhance intestinal drug absorption and increase drug penetration to biologi
24 thelium and lack of prediction potential for drug absorption and metabolism during the preclinical st
25 ivo studies, which reflect the net effect of drug absorption and metabolism in all organs of the body
26 ks of the leading intestinal models used for drug absorption and metabolism studies.
27  epithelial damage caused increased systemic drug absorption and penetration of MPP into colorectal t
28 thylbenz[a]anthracene in vivo, demonstrating drug absorption and tissue distribution leading to pharm
29  is apparently nearly entirely accessible to drug absorption, and (iv) the relative "leakiness" of th
30 oing PPCI, crushed prasugrel leads to faster drug absorption, and consequently, more prompt and poten
31  thereby effectively mitigating the impaired drug absorption at the elevated pH relevant for absorpti
32 lutary effects extend to diminished systemic drug absorption, augmented ocular bioavailability, and t
33 ples can be used to directly measure topical drug absorption, biopsies are invasive and not practical
34  a high-speed channel, thereby enhancing the drug absorption by tumor cells.
35  lipid system function and overall impact on drug absorption can aid in the understanding of drug-lip
36 doresistance, reflecting delayed and reduced drug absorption, complicates enteric coated but not imme
37 ics in vivo and the consequential effects on drug absorption distribution, metabolism, excretion, and
38 s associated with critical illness may alter drug absorption, distribution, and clearance, and concom
39 f fundamental importance and a key factor in drug absorption, distribution, and development.
40  enzymes, many of which are also involved in drug absorption, distribution, metabolism and eliminatio
41                             Genes central to drug absorption, distribution, metabolism and eliminatio
42 unt of important environmental influences on drug absorption, distribution, metabolism and excretion.
43              These properties, which include drug absorption, distribution, metabolism, and excretion
44                                              Drug absorption, distribution, metabolism, and excretion
45  containing evidence of NNS interacting with drug absorption, distribution, metabolism, and excretion
46 quencies in 58 pharmacogenes associated with drug absorption, distribution, metabolism, and excretion
47 hysiological processes in fish that underlie drug absorption, distribution, metabolism, excretion and
48 f PK and PD parameters and the prediction of drug absorption, distribution, metabolism, excretion and
49 currently under investigation as a potential drug absorption enhancer.
50 patients showed no improvement in intestinal drug absorption even a week after hemorrhage.
51 micro- and nanoplastics with drugs can alter drug absorption, facilitate drug transport to new locati
52 ux are two important biochemical barriers to drug absorption from the intestine.
53 bilize drug supersaturation and enhance oral drug absorption has recently garnered considerable inter
54 g release to in vivo drug release or in vivo drug absorption, has been explored chiefly for oral exte
55 r-Nelson method to obtain percent of in vivo drug absorption in postmenopausal women.
56 ure system provided higher predictability of drug absorption in the human GI tract than a Caco-2 Tran
57 evious research has demonstrated compromised drug absorption in this group of patients.
58 ontributing factor to poor immunosuppressive drug absorption in this patient and others.
59 dhesion to intestinal mucosa, enhancement of drug absorption in vitro (Caco-2 monolayer transport) an
60       However, they do not generally predict drug absorption in vivo.
61 It is thus important to address the issue of drug absorption into device material.
62                              We investigated drug absorption into microfluidic devices by treating mu
63 his interplay and its potential relevance to drug absorption is an important goal, as a large proport
64                      The effect of lipids on drug absorption is currently not quantitatively predicta
65 n (CPR) is <20% of normal, and transalveolar drug absorption is likely to be minimal.
66 urst release phases may not be comparable if drug absorption is rate-limiting at this stage.
67                         Intestinal lymphatic drug absorption is seldom explored, although reduced tox
68         Following SAH, significantly reduced drug absorption may be attributed to decreased intestina
69 hat physiological PK modelling of first-pass drug absorption, metabolism and excretion in humans-usin
70 blems in Systems Biology: a pharmacokinetics drug absorption model and an ultradian endocrine model f
71           Ensuring reliable gastrointestinal drug absorption of orally administered immunosuppressive
72  means to increase the low and variable oral drug absorption of transporter substrates while decreasi
73 ein binding and ECM components in predicting drug absorption, offering a promising tool for the devel
74                                      In vivo drug absorption (or release) should be measured to provi
75 me, no patients had a history of liver toxic drug absorption, patent viral infection, or any histopat
76 n vitro drug release kinetics showed in vivo drug absorption profiles consistent with in vitro trend.
77  of prodrug hydrolysis were reduced to favor drug absorption rather than drug precipitation.
78 ck onset of action was indicated by the fast drug absorption shown in mice.
79                40 has the potential to block drug absorption through OATP2B1 inhibition in vivo.
80                                  The site of drug absorption was revealed by high spatial resolution
81 hanges in the lung can also result in slower drug absorption, which is further compounded by disease
82  highlight the in vitro advances in modeling drug absorption, which more faithfully reflect human int
83 f drug permeation (X) and in vivo percent of drug absorption (Y) for these three estradiol TDDS was c